Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis (NCT06948487) | Clinical Trial Compass
RecruitingNot Applicable
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
South Korea12,000 participantsStarted 2025-06-17
Plain-language summary
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
Who can participate
Age range19 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
* Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
* Subjects who present with at least one subjective symptom requiring medical treatment
* Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
Exclusion Criteria:
* Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
* Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
What they're measuring
1
The proportion of subjects with improvement in subjective symptoms